CDC Vaccine Panel Votes to Delay Hepatitis B Birth Dose for Newborns With Virus-Negative Mothers

The CDC’s vaccine advisory committee has voted to change long-standing recommendations for the hepatitis B vaccine birth dose. In an 8–3 decision, the panel supported delaying the first dose until a child is 2 months old for babies born to mothers who test negative for hepatitis B, shifting from the universal birth dose guidance followed in the U.S. for more than 30 years.

Panel Calls for Individual Decision-Making

Under the new recommendation, parents are advised to consult with a healthcare provider to determine whether and when to give the hepatitis B vaccine at birth when the mother is confirmed virus-negative.

Several pediatric experts strongly opposed the change, warning that delaying the birth dose could leave newborns unprotected during a critical window. Decades of data show the vaccine is safe, effective, and responsible for a 99% decrease in hepatitis B infections among U.S. infants and children.

Debate and Confusion Surround the Vote

The decision followed a tense two-day meeting marked by disagreements and procedural confusion. Some panel members argued that no new scientific evidence justified changing the long-standing recommendation. Others raised concerns about limited safety data—a claim rejected by multiple infectious disease specialists who cited extensive research demonstrating the vaccine’s strong safety record.

The advisory group also voted 6–4, with one abstention, to recommend that parents discuss with their doctors whether their children should be tested after the first vaccine dose to confirm protective antibody levels. The vaccine is typically given as a three-dose series.

Medical Groups Warn of Increased Risk to Newborns

Major medical organizations expressed concern that delaying the birth dose could undermine decades of progress in preventing hepatitis B transmission. Experts note:

• Hepatitis B can cause chronic liver disease, cancer, and early death.
• Infants infected at birth or within their first year have a 90% chance of developing chronic hepatitis B.
• Roughly 1 in 6 pregnant women are not properly screened during prenatal care, making the birth dose a critical safety net.
• Studies show no benefit to delaying the vaccine, and severe reactions are extremely rare.

The universal birth dose has long protected newborns when prenatal screening fails, when results are miscommunicated, or when infants receive inconsistent follow-up care.

National and Political Response

Some political leaders and physicians criticized the committee’s vote, arguing it could lead to a rise in preventable infections. Others praised the shift toward individualized decision-making.

The recommendation now goes to the CDC director for review. States ultimately decide their own vaccine requirements, and insurance coverage may also be affected depending on future CDC guidance.

Why Newborns Have Traditionally Received the Hepatitis B Vaccine

Hepatitis B is spread through blood and bodily fluids and can survive on contaminated surfaces. Schools and childcare facilities commonly require hepatitis B vaccination due to its contagious nature.

The newborn dose has historically been critical because:

• Many infected mothers are not identified before delivery.
• Babies infected early in life face severe long-term health risks.
• Universal vaccination dramatically reduced hepatitis B transmission in the U.S.

Pediatric specialists emphasize that delaying the first dose could leave infants unprotected during a period when even one missed case can lead to lifelong illness.